相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。S2k‐Leitlinie zur Therapie des Pemphigus vulgaris/foliaceus und des bullösen Pemphigoids: 2019 Update
Enno Schmidt et al.
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT (2020)
Dipeptidyl-peptidaseIVinhibitors (DPP4i)-associated bullous pemphigoid: Estimating the clinical profile and exploring intraclass differences
Khalaf Kridin
DERMATOLOGIC THERAPY (2020)
Gliptin-Associated Bullous Pemphigoid: A Valuable Model of the Mechanism of Breakdown of Immune Tolerance against BP180
Wataru Nishie et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2019)
Dipeptidyl Peptidase 4 Inhibitors and the Risk of Bullous Pemphigoid Among Patients With Type 2 Diabetes
Antonios Douros et al.
DIABETES CARE (2019)
Preferential Reactivity of Dipeptidyl Peptidase-IV Inhibitor-Associated Bullous Pemphigoid Autoantibodies to the Processed Extracellular Domains of BP180
Yosuke Mai et al.
FRONTIERS IN IMMUNOLOGY (2019)
Dipeptidyl Peptidase-4 Inhibitor-Associated Bullous Pemphigoid
Kaisa Tasanen et al.
FRONTIERS IN IMMUNOLOGY (2019)
A Cross-Sectional Study Comparing the Prevalence of Bullous Pemphigoid Autoantibodies in 275 Cases of Type II Diabetes Mellitus Treated With or Without Dipeptidyl Peptidase-IV Inhibitors
Kentaro Izumi et al.
FRONTIERS IN IMMUNOLOGY (2019)
Higher Frequency of Dipeptidyl Peptidase-4 Inhibitor Intake in Bullous Pemphigoid Patients than in the French General Population
Marthe Plaquevent et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2019)
Association of Dipeptidyl Peptidase 4 Inhibitor Use With Risk of Bullous Pemphigoid in Patients With Diabetes
Seon Gu Lee et al.
JAMA DERMATOLOGY (2019)
Assessment of the Prevalence of Mucosal Involvement in Bullous Pemphigoid
Khalaf Kridin et al.
JAMA DERMATOLOGY (2019)
Dipeptidyl peptidase IV inhibitor-associated bullous pemphigoid: a recently recognized autoimmune blistering disease with unique clinical, immunological and genetic characteristics
Wataru Nishie
IMMUNOLOGICAL MEDICINE (2019)
Gliptin-associated Bullous Pemphigoid and the Expression of Dipeptidyl Peptidase-4/CD26 in Bullous Pemphigoid
Outi Lindgren et al.
ACTA DERMATO-VENEREOLOGICA (2019)
Subepidermal autoimmune bullous diseases: overview, epidemiology, and associations
Khalaf Kridin
IMMUNOLOGIC RESEARCH (2018)
Unique clinical and serological features of bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitors
H. Horikawa et al.
BRITISH JOURNAL OF DERMATOLOGY (2018)
Decrease in eosinophils infiltrating into the skin of patients with dipeptidyl peptidase-4 inhibitor-related bullous pemphigoid
Chika Chijiwa et al.
JOURNAL OF DERMATOLOGY (2018)
HLA-DQB1*03:01 as a Biomarker for Genetic Susceptibility to Bullous Pemphigoid Induced by DPP-4 Inhibitors
Hideyuki Ujiie et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2018)
Vildagliptin Significantly Increases the Risk of Bullous Pemphigoid: A Finnish Nationwide Registry Study
Outi Varpuluoma et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2018)
Detection and characterization of IgG, IgE, and IgA autoantibodies in patients with bullous pemphigoid associated with dipeptidyl peptidase-4 inhibitors
Luca Fania et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2018)
Dipeptidyl peptidase IV inhibitors, a risk factor for bullous pemphigoid: Retrospective multicenter case-control study from France and Switzerland
Michael Benzaquen et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2018)
Association of Bullous Pemphigoid With Dipeptidyl-Peptidase 4 Inhibitors in Patients With Diabetes Estimating the Risk of the New Agents and Characterizing the Patients
Khalaf Kridin et al.
JAMA DERMATOLOGY (2018)
Dipeptidyl-peptidase IV inhibitor-associated bullous pemphigoid: A systematic review and meta-analysis
Khalaf Kridin et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2018)
Bullous pemphigoid in patients with DPP-4 inhibitors at the onset of disease: does this differ from common bullous pemphigoid?
Aikaterini Patsatsi et al.
EUROPEAN JOURNAL OF DERMATOLOGY (2018)
The Growing Incidence of Bullous Pemphigoid: Overview and Potential Explanations
Khalaf Kridin et al.
FRONTIERS IN MEDICINE (2018)
Use of Dipeptidyl-Peptidase IV Inhibitors and Bullous Pemphigoid
Clara Schaffer et al.
DERMATOLOGY (2017)
Bullous pemphigoid and dipeptidyl peptidase IV inhibitors: a case-noncase study in the French Pharmacovigilance Database
J. Bene et al.
BRITISH JOURNAL OF DERMATOLOGY (2016)
Autoantibody Profile Differentiates between Inflammatory and Noninflammatory Bullous Pemphigoid
Kentaro Izumi et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2016)
The carbohydrate switch between pathogenic and immunosuppressive antigen-specific antibodies
Mattias Collin et al.
EXPERIMENTAL DERMATOLOGY (2013)
Definitions and outcome measures for bullous pemphigoid: Recommendations by an international panel of experts
Dedee F. Murrell et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2012)
分享论文
